A review of the imaging manifestations of immune check point inhibitor toxicities
- 1 August 2020
- journal article
- review article
- Published by Elsevier in Clinical Imaging
- Vol. 64, 70-79
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4Arthritis & Rheumatology, 2014
- Ipilimumab-Associated Colitis: CT FindingsAmerican Journal of Roentgenology, 2013
- Ipilimumab associated hepatitis: imaging and clinicopathologic findingsInvestigational New Drugs, 2013
- Decade of Molecular Targeted Therapy: Abdominal Manifestations of Drug Toxicities???What Radiologists Should KnowAmerican Journal of Roentgenology, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Ipilimumab-Induced Hypophysitis: MR Imaging FindingsAmerican Journal of Neuroradiology, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Elucidating mechanisms of drug-induced toxicityNature Reviews Drug Discovery, 2005
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996